Abbott (NYSE:ABT) announced that Health Canada has approved its FreeStyle Libre 2 continuous glucose monitor for adults and children.
The next-generation, wearable, sensor-based CGM technology with real-time alarms is approved for use in adults and children (four years old and up) and will be priced the same as the current FreeStyle Libre system, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.